Andre F Batista1, Tayná Rody1, Leticia Forny-Germano1, Suzana Cerdeiro1, Maria Bellio2, Sergio T Ferreira1,3, Douglas P Munoz4, Fernanda G De Felice5,6,7. 1. Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, CCS, room H2-019, Rio de Janeiro, RJ, 21941-590, Brazil. 2. Department of Immunology, Institute of Microbiology Paulo de Góes, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brazil. 3. Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brazil. 4. Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, K7L3N6, Canada. 5. Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, CCS, room H2-019, Rio de Janeiro, RJ, 21941-590, Brazil. felice@bioqmed.ufrj.br. 6. Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, K7L3N6, Canada. felice@bioqmed.ufrj.br. 7. Department of Psychiatry, Queen's University, Kingston, Ontario, K7L3N6, Canada. felice@bioqmed.ufrj.br.
Abstract
BACKGROUND: The lack of effective treatments for Alzheimer's disease (AD) reflects an incomplete understanding of disease mechanisms. Alterations in proteins involved in mitochondrial dynamics, an essential process for mitochondrial integrity and function, have been reported in AD brains. Impaired mitochondrial dynamics causes mitochondrial dysfunction and has been associated with cognitive impairment in AD. Here, we investigated a possible link between pro-inflammatory interleukin-1 (IL-1), mitochondrial dysfunction, and cognitive impairment in AD models. METHODS: We exposed primary hippocampal cell cultures to amyloid-β oligomers (AβOs) and carried out AβO infusions into the lateral cerebral ventricle of cynomolgus macaques to assess the impact of AβOs on proteins that regulate mitochondrial dynamics. Where indicated, primary cultures were pre-treated with mitochondrial division inhibitor 1 (mdivi-1), or with anakinra, a recombinant interleukin-1 receptor (IL-1R) antagonist used in the treatment of rheumatoid arthritis. Cognitive impairment was investigated in C57BL/6 mice that received an intracerebroventricular (i.c.v.) infusion of AβOs in the presence or absence of mdivi-1. To assess the role of interleukin-1 beta (IL-1β) in AβO-induced alterations in mitochondrial proteins and memory impairment, interleukin receptor-1 knockout (Il1r1-/-) mice received an i.c.v. infusion of AβOs. RESULTS: We report that anakinra prevented AβO-induced alteration in mitochondrial dynamics proteins in primary hippocampal cultures. Altered levels of proteins involved in mitochondrial fusion and fission were observed in the brains of cynomolgus macaques that received i.c.v. infusions of AβOs. The mitochondrial fission inhibitor, mdivi-1, alleviated synapse loss and cognitive impairment induced by AβOs in mice. In addition, AβOs failed to cause alterations in expression of mitochondrial dynamics proteins or memory impairment in Il1r1-/- mice. CONCLUSION: These findings indicate that IL-1β mediates the impact of AβOs on proteins involved in mitochondrial dynamics and that strategies aimed to prevent pathological alterations in those proteins may counteract synapse loss and cognitive impairment in AD.
BACKGROUND: The lack of effective treatments for Alzheimer's disease (AD) reflects an incomplete understanding of disease mechanisms. Alterations in proteins involved in mitochondrial dynamics, an essential process for mitochondrial integrity and function, have been reported in AD brains. Impaired mitochondrial dynamics causes mitochondrial dysfunction and has been associated with cognitive impairment in AD. Here, we investigated a possible link between pro-inflammatory interleukin-1 (IL-1), mitochondrial dysfunction, and cognitive impairment in AD models. METHODS: We exposed primary hippocampal cell cultures to amyloid-β oligomers (AβOs) and carried out AβO infusions into the lateral cerebral ventricle of cynomolgus macaques to assess the impact of AβOs on proteins that regulate mitochondrial dynamics. Where indicated, primary cultures were pre-treated with mitochondrial division inhibitor 1 (mdivi-1), or with anakinra, a recombinant interleukin-1 receptor (IL-1R) antagonist used in the treatment of rheumatoid arthritis. Cognitive impairment was investigated in C57BL/6 mice that received an intracerebroventricular (i.c.v.) infusion of AβOs in the presence or absence of mdivi-1. To assess the role of interleukin-1 beta (IL-1β) in AβO-induced alterations in mitochondrial proteins and memory impairment, interleukin receptor-1 knockout (Il1r1-/-) mice received an i.c.v. infusion of AβOs. RESULTS: We report that anakinra prevented AβO-induced alteration in mitochondrial dynamics proteins in primary hippocampal cultures. Altered levels of proteins involved in mitochondrial fusion and fission were observed in the brains of cynomolgus macaques that received i.c.v. infusions of AβOs. The mitochondrial fission inhibitor, mdivi-1, alleviated synapse loss and cognitive impairment induced by AβOs in mice. In addition, AβOs failed to cause alterations in expression of mitochondrial dynamics proteins or memory impairment in Il1r1-/- mice. CONCLUSION: These findings indicate that IL-1β mediates the impact of AβOs on proteins involved in mitochondrial dynamics and that strategies aimed to prevent pathological alterations in those proteins may counteract synapse loss and cognitive impairment in AD.
Authors: Mark J Barsoum; Hua Yuan; Akos A Gerencser; Géraldine Liot; Yulia Kushnareva; Simone Gräber; Imre Kovacs; Wilson D Lee; Jenna Waggoner; Jiankun Cui; Andrew D White; Blaise Bossy; Jean-Claude Martinou; Richard J Youle; Stuart A Lipton; Mark H Ellisman; Guy A Perkins; Ella Bossy-Wetzel Journal: EMBO J Date: 2006-07-27 Impact factor: 11.598
Authors: Heng Du; Lan Guo; Shiqiang Yan; Alexander A Sosunov; Guy M McKhann; Shirley ShiDu Yan Journal: Proc Natl Acad Sci U S A Date: 2010-10-11 Impact factor: 11.205
Authors: Colin L Masters; Randall Bateman; Kaj Blennow; Christopher C Rowe; Reisa A Sperling; Jeffrey L Cummings Journal: Nat Rev Dis Primers Date: 2015-10-15 Impact factor: 52.329
Authors: John Man Tak Chu; Amina Abulimiti; Brian Shing Hei Wong; Guan Ding Zhao; Shi Hang Xiong; Ming Ming Zhao; Yingyi Wang; Ying Chen; Jiaqi Wang; Yan Zhang; Raymond Chuen Chung Chang; Hua Yu; Gordon Tin Chun Wong Journal: Front Pharmacol Date: 2022-03-17 Impact factor: 5.810
Authors: Shanshan Wang; Taiga Ichinomiya; Paul Savchenko; Swetha Devulapalli; Dongsheng Wang; Gianna Beltz; Takashi Saito; Takaomi C Saido; Steve L Wagner; Hemal H Patel; Brian P Head Journal: Front Mol Neurosci Date: 2022-07-29 Impact factor: 6.261